ACXP · Acurx Pharmaceuticals, Inc.
$1.41
-0.04 (-2.76%)
At close · Jul 24
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$6.10M
Shares
4.30M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Chairman | $1,463,430 |
| David P. Luci | CEO | $1,431,383 |
| Robert Shawah | CFO | $907,463 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Chairman | $1,056,436 |
| David P. Luci | CEO | $1,023,878 |
| Robert Shawah | CFO | $675,038 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Chairman | $677,186 |
| David P. Luci | CEO | $655,000 |
| Robert Shawah | CFO | $375,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Chairman | $4,509,094 |
| David P. Luci | CEO | $4,487,465 |
| Robert Shawah | CFO | $1,462,738 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert DeLuccia | Chairman | $617,570 |
| David P. Luci | CEO | $596,037 |
| Robert Shawah | CFO | $152,500 |